July 2, 1996 - Anderson Lab



October 15, 2017

CURRICULUM VITAE

Name: Clark Lawrence Anderson

S.S. Number: 577-52-4840

Present Position: Professor

Division of Immunology

Department of Internal Medicine

College of Medicine, The Ohio State University

Mail: The Ohio State University

012k The Heart & Lung Research Institute

473 West Twelfth Avenue

Columbus, OH 43210

Voice: 614-247-7650

Fax: 614-247-7669

Internet: anderson.48@osu.edu

Beeper: 614-730-6739

Website:

Faculty Appointments:

1977-1983 Assistant Professor of Medicine; University of Rochester School of Medicine, Rochester, NY

1982-1986 Assistant Professor of Microbiology; University of Rochester School of Medicine, Rochester, NY

1983-1986 Associate Professor of Medicine; University of Rochester School of Medicine, Rochester, NY

1986-2005 Professor, Department of Internal Medicine (primary); The Ohio State University College of Medicine, Columbus, OH

1987- Professor, Department of Molecular and Cellular Biochemistry (secondary); The Ohio State University College of Medicine, Columbus, OH

1987-1998 Professor, Department of Molecular Genetics (secondary); The Ohio State University College of Biological Sciences, Columbus, OH

2005- Professor Emeritus, OSU Department of Internal Medicine.

Education:

1955-1957 Brown University, Providence, Rhode Island

1957-1960 University of Arizona, Tucson, AZ, B.A., 1960

1960-1964 University of Chicago, School of Medicine, M.D., 1964

1964-1965 University of Chicago, Department of Biochemistry, Ph.D. student

Armed Services:

1966-1969 Major, U.S. Army Medical Corps, Vietnam War Doctors’ Draft

Clinical Training

1965-1966 Internship in Internal Medicine; Dr. Gordon Meiklejohn, University of Colorado, Denver, CO

1969-1971 Residency in Internal Medicine; Dr. Gordon Meiklejohn, University of Colorado, Denver, CO. Board Qualified

1974-1975 Fellowship in Clinical Immunology; Dr. Richard Farr; National Jewish Center and University of Colorado, Denver, CO

Research Training:

1971-1972 Postdoctoral Research Fellowship in Immunology; Drs. Percy Minden and Richard Farr; National Jewish Center, Denver, CO

1972-1974 Research Fellowship in Immunology; Dr. Howard Grey; National Jewish Center, Denver, CO

1975-1977 Leukemia Society of America Special Fellowship; Dr. Grey

Licensure:

National Board of Medical Examiners

Colorado, #16972

New York, #130699

Ohio, #54371

Honors and Awards:

1960 High honors with baccalaureate degree; U. Arizona

1960 Phi Kappa Phi National Scholastic Honorary, U. Arizona

1975-1977 Leukemia Society of America Special Fellowship, U. Colorado

1978 Buswell Foundation Faculty Award; U. Rochester

1979-1984 Research Career Development Award, NIAID, NIH

1981 WHO Nomenclature Committee on Fc Receptors

1982- Ad Hoc Reviewer: NIH study sections and site visits, National Science Foundation, Veterans Administration, Canadian Red Cross, The Netherlands NIH, Biochemistry Journal, Journal of Clinical Immunology, Science, Journal of Clinical Investigation, Journal of Leukocyte Biology, Cellular Immunology, Journal of Immunology, Blood, Journal of Pediatric Infectious Diseases, Journal of Immunopharmacology, Immunity, PNAS, Journal of Experimental Medicine, Journal of Molecular Evolution, Journal of Biological Chemistry, Gene, Austrian Science Fund, Molecular and Cellular Biology, Biotechnology and Bioengineering, Hungarian Scientific Research Fund, Journal of Histochemistry & Cytochemistry, Analytical Biochemistry, Journal of Pharmacology and Experimental Therapeutics, Nature Reviews Nephrology, BioMed Research International, PLoS One, Structure

1987-1991 Medical Biochemistry Study Section (2), DRG, NIH, regular member

1988-1995 Member Board of Scientific Directors, Medarex, Inc., Annandale, NJ

1989-1998 Associate Editor, Journal of Clinical Immunology

1992 V International Leukocyte Workshop, Cluster Co-Chairman

1994 Distinguished Scholar Award; OSU

1996 Journal of Leukocyte Biology Outstanding Review Award

1998-2002 Section Editor, Journal of Immunology

National Professional Organizations:

1975-1991 American Academy of Allergy and Clinical Immunology

1976-1991 American Federation for Clinical Research

1976- American Association of Immunologists

1986-1993 Reticuloendothelial Society

1987-1994 American Society for Cell Biology

University Committees and Offices:

1988-1990 The OSU Medical Scientist Program (M.D./Ph.D. program), Director

1988-1991 The OSU Faculty Senate

1988-1991 The OSU Medical Faculty Caucus

1989 The OSU Search Committee for Dean of College of Biological Sciences

1992-1994 College of Medicine Graduate Education Committee

1992-1996 Dept Medicine Promotions and Tenure Committee; Chair, 1995-1996.

1993- OSU College of Medicine Research Committee

1993- OSU Department of Medicine Research Space Committee

1994 College of Medicine Search Committee for Chair of Department of Medical Biochemistry.

1994- Department of Medicine Ad Hoc Committee on Promotions Criteria

1995-1996 OSU Research Foundation Principal Investigator Advisory Committee

1996-1997 Advisory Committee for the Molecular Medicine Initiative

2001- Department of Medicine Committee on Incentives

2003- Department of Medicine Research Committee

2011- 2013 HLRI Space Committee

Invited Presentations at National or International Meetings (date, event, place, host):

4/86; Minisymposium, FASEB Annual Meeting; St. Louis, MO

4/86; FASEB Annual Meeting; St. Louis, MO

7/86; Fc Receptor Symposium; Toronto, Canada

7/86; VI International Congress Immunology; Toronto, Canada

9/86; Reticuloendothelial Society; Denver, CO

6/87; FASEB Summer FcR Conference, Saxtons River, VT

9/87; Platelet Immunology Conference; Milwaukee, WI

3/88; Sandoz symposium on Monoclonal Antibodies; Amsterdam, The Netherlands

4/88; Joint French and British Societies of Immunology; Paris, France

4/88; British Society of Biochemistry; Sheffield, England

5/88; Minisymposium Chair; FASEB Annual Meeting; Las Vegas, NV

5/88; Presentation; FASEB Annual Meeting; Las Vegas, NV

3/89; Sandoz Symposium on Autoimmunity; Scottsdale, AZ; Dr. Irwin Gelfand

3/89; Faseb Annual Meeting; New Orleans, LA

10/89; Society of Leukocyte Biology; Marco Island, FL

7/90; FASEB Summer FcR Conference, Copper Mountain, CO

7/90; Poster; FASEB Summer Conference; Copper Mountain, CO (G. Anderson, Ph.D.)

7/90; Poster; FASEB Summer Conference; Copper Mountain, CO (G. Kindt, Ph.D.)

9/91; Pediatric AIDS Foundation; Santa Barbara, CA; Arthur Ammann, M.D.

4/92; FASEB Annual Meeting; Anaheim, CA

8/92; VIII International Congress Immunology; Budapest, Hungary

11/93; V International CD Workshop; Boston, MA

2/96; Oral Immunology and Microbiology Research Group; Orlando; Gary Wilson, Ph.D.

3/97; North American Trophoblast Meeting, San Diego; Nicholas Illsley, Ph.D.

11/01; American College Rheumatology; San Francisco; Jane Salmon, M.D. (cancelled, illness)

6/02; Frontiers in Reproduction; Boston; Joan Hunt, Ph.D.

7/02; Society for the Study of Reproduction; Baltimore; Joan Hunt, Ph.D.

5/03; The Karl Landsteiner Lecture; CLB; Amsterdam, NL; Masja de Haas, Ph.D.

9/03; Howard M. Grey Festschrift; LaJolla, CA; Mitch Kronenberg, Ph.D.

6/06; AAPS National Biotechnology Conference: Boston; Joseph Balthasar, Ph.D.

8/08; International Society Hepatic Sinusoidal Research; Tromso, Norway

3/10; Gordon Conference on Antibody action; Ventura, CA

8/10; International Society Hepatic Sinusoidal Research; Pasadena, CA

Presentations at Other Academic Institutions:

3/86; Dept Medicine; Rush Medical Colege; Henry Gewurz, M.D., Ph.D.

3/86; Dept Medicine, Univ Illinois; John Scosey, M.D., Ph.D.

1/87; Cetus Immune, Inc.; Palo Alto, CA; David Ring, Ph.D.

1/87; Dept Medicine; UCSF; San Francisco, CA; Gary Peltz, M.D., Ph.D.

2/87; Dept Pathology; Univ Iowa; Iowa City, IO; Richard Lynch, M.D.

3/87; Dept Micro, Dartmouth Conference; Squam Lake, VT; Michael Fanger, Ph.D.

4/87; Dept Genetics; Univ Turino; Torino, Italy; Fabio Malavasi, M.D.

4/87; Dept Pharm; Univ Milan; Milan, Italy; Paolo Ricciardi-Castagnoli, Ph.D.

6/87; Proctor & Gamble; Cincinnati, OH; Robert Singer, Ph.D.

6/87; Medarex, Inc. Minary Conf Center; Squam Lake, VT; Michael Fanger, Ph.D.

6/88; Medarex, Inc. Minary Conf Center; Squam Lake, VT; Michael Fanger, Ph.D.

6/88; Dept Micro; Dartmouth Medical School; Michael Fanger, Ph.D.

11/88; Dept Medicine; University of Rochester; R. John Looney, M.D.

11/88; Dept Chemistry, Cornell University; Barbara Baird, Ph.D.

3/88; Dept Medicine; Univ Leuven; Leuven, Belgium; Jan Ceuppens, M.D., Ph.D.

3/88; Dept Medicine; University Nihmegen, Nijmegen, Netherlands; Wil Tax, Ph.D.

3/88; Red Cross Blood Center; Amsterdam, The Netherlands; Pedro Tetteroo, Ph.D.

3/88; Centocor Europe, B.V.; Leiden, The Netherlands; Pedro Tetteroo, Ph.D.

10/89; Medarex, Inc. Minary Conference; Squam Lake, NH; Michael Fanger, Ph.D.

5/90; Dept Micro; Univ Kansas; Kansas City, KA; Tsuneo Susuki, M.D., Ph.D.

6/90; Minary FcR Symposium; Squam Lake, NH; Michael Fanger, Ph.D.

5/91; Minary FcR Conference; Squam Lake, NH; Michael Fanger, Ph.D.

9/91; Dept Bioscience; UCSB, Santa Barbara, CA; Duane Sears, Ph.D.

8/92; Dept Immunology; Univ Utrecht, The Netherlands; Jan Van de Winkel, Ph.D.

3/93; Immunol Program; Univ Cincinnati; OH; Alvin E. Davis, M.D.

4/93; Univ Wisconsin; Milwaukee, WI; Richard Aster, M.D.

6/93; Immunology Program; Case-Western Reserve; Michael Tosi, M.D.

7/93; Scripps Clinic and Research Foundation; John Curnutte, M.D., Ph.D.

10/93; Dept Immunol; Univ Toronto, Toronto, Canada; Michel Klein, M.D.

12/95; Dept Microbiology; Dartmouth, Lebanon, NH; Michael Fanger, Ph.D.

5/97; Jackson Laboratories Research Institute, Bar Harbor, ME, Derry Roopenian, Ph.D.

10/97; Cornell University Medical Center, New York City, NY, Jane Salmon, M.D.

1/98; Immunology Program; Univ. of Pittsburgh, Pittsburgh, PA; Penelope Morel, M.D.

11/99; Immunology; Univ. New Mexico, Albuquerque, NM; Terry DuClos, M.D.,Ph.D.

10/02; Immunology; Albany Medical College, Albany, NY; Edward Gosselin, Ph.D.

12/02; Biogen, Inc.; Cambridge, MA; Graham Farrington, Ph.D.

10/03; LaJolla Inst Allergy & Immunology; CA; Howard Grey, M.D.

5/03; Genmab, Inc.; Utrecht, NL; Jan van de Winkel, Ph.D.

4/04; Dept Pathology; Emory University; Atlanta, GA; Periasamy Selvaraj, Ph.D.

10/05; SUNY Buffalo; Joseph Balthasar, Ph.D.

9/06; John P. Leddy Festschrift; Rochester, NY; Ignacio Sanz, M.D. cancelled;

10/06; Amgen Mountain View (Avidia); CA; Kevin Moore, Ph.D.

5/07; Adnexus Therapeutics; Boston; Eric Furfine, Ph.D.

5/08; Merck, Philadelphia; Thomayant Prueksaritanont, Ph.D.

1/12; St.Louis University; Mark Buller, PhD.

Presentations at Ohio State University:

10/86; Immunology Seminar Series, Col of Med; Rolf Barth, M.D.

11/86; Dept Physiol Chem; Col of Med; Gerald Brierley, Ph.D.

1/87; Dept Micro; Col of Biosci; Richard Mortensen, Ph.D.

11/87; Dept Biochemistry; Col of Biosci; George Marzluf, Ph.D.

1/88; MolGen 705; Col of Biosci; Berl Oakley, Ph.D.

1/89; Immunology Seminar Series; Col of Med; Rolf Barth, M.D.

2/89; MolGen705; Col of Biosci; Berl Oakley, Ph.D.

3/89; Dept Surgery; Col of Med; Charles Orosz, Ph.D.

2/90; MolGen 705; Col of Biosci; Berl Oakley, Ph.D.

11/91; Dept Micro and Immunol; Col of Med; Ronald Glaser, Ph.D.

2/92; MolGen 705; Col of Biosci; Berl Oakley, Ph.D.

2/93; MolGen 705; Col of Biosci; Berl Oakley, Ph.D.

2/95; Dept Med Biochemistry; Col of Med; Gerald Brierly, Ph.D

4/95; Dept Medicine Grand Rounds; Ernest Mazzaferri, M.D.

6/95; Grants Colloquium; Col of Med; Daniel Sedmak, M.D.

12/95; Dept Ob/Gyn; Col of Med; Steven Gabbe, M.D.

1/96; Immunology Program; Rolf Barth, M.D.

2/98; Dept Microbiology; Col of Biosci: Mark Coggeshall, Ph.D.

4/98; Heart-Lung Institute; Mark Wewers, M.D.

…record not continued

Trainees: Postdoctoral fellows and Ph.D. students trained by Dr. Anderson: Listed chronologically by name, degrees and institution; position and dates in my lab; last known whereabouts. List prepared March 31, 2003; last updated October 12, 2007: At last count 11/31of my trainees had academic jobs.

Postdoctoral fellows:

Charles Beauchamp, M.D. Ph.D. Duke; fellow 1979-1980; General Medicine, University of Michigan

Linda Ludwig, M.D. Rochester; fellow 1982; Department of Pediatrics, University of Rochester, NY

Douglas H. Jones, M.D. Johns Hopkins; fellow 1982-1985; Adjunct Assistant Professor, U. Rochester.

R. John Looney, M.D. Rochester; fellow 1984-1986; Professor, Department of Medicine, U. Rochester.

George Anderson, Ph.D. OSU; fellow 1987-1990, NRSA; Scientist, Naval Research Lab; Wash D.C.

Gary Kindt, M.D. OSU; fellow 1988-1990; private practice, pulmonary medicine, MI

Donald M. Eicher, M.D. OSU; fellow 1989-1990; Assistant Professor, Case Western Reserve

Sharda Hebbar, Ph.D. OSU; fellow 1989; leave of absence

Jan van de Winkel, Ph.D. Nijmegen; fellow 1990-1991; Professor, Utrecht, NL; CEO Genmab Inc.

Alaa Ahmed, Ph.D. Glasgow; fellow 1991-1993; Research Scientist, University of Glasgow, Scotland

Nagaradona Harindranath, Ph.D.; fellow 1992-1994; Staff Scientist, NIH

Linda Ernst, Ph.D. Utrecht; student, fellow 1988-1995; Asst Professor, U. Pittsburgh, PA, LOA.

Anne-Marie Duchemin, M.D. Paris; fellow 1991-1996; Research Associate Professor, OSU

Kathleen Miller, Ph.D. OSU; fellow 1997-1998; Staff Scientist, DNAX, Palo Alto, CA

Timothy Lyden, Ph.D. Maine; fellow 1998-2001; Assistant Professor; U. Wisconsin River Falls.

Susheela Tridandapani, Ph.D. OSU; fellow 1998-2001; LLS Fellow 2000-2003; Professor; OSU

Samina Mehnaz, Ph.D. Pakistan; fellow 2000-2003; Assoc Prof. Univ Punjab. Lahore, Pakistan

Cynthia L. Bronson, Ph.D. OSU; fellow 2002-2005; Lecturer OSU Department of EEOB.

Sudha Mohanty, Ph.D. Jawaharlal Nehru University, New Delhi; fellow 2003-present

Jonghan Kim, Ph.D. OSU; fellow 2004-2007. Fellow Harvard. Dr. Wessling-Resnick lab.

Chaity Chaudhury, Ph.D. OSU; fellow 2005-2006; Scientist Medimmune; Gaithersburg, MD.

Latha P. Ganesan, Ph.D. Madurai Kamaraj Univ; fellow 2007-present.

Jessica Mates, Ph.D. OSU Virologist. 2014 – 2016

Zhili Yao, Ph.D. OSU Organic Chemist. 2015 – present

Osan Suer, M.D. Case Western. 2016 - present

Graduate Students for the Ph.D. degree:

George Chacko, Ph.D. OSU in Biochem; student 1990-1995. SRA; NIH; Bethesda, MD.

Linda Ernst, Ph.D. Utrecht in Immunol.; student 1989-1995. Left science after Asst. Prof, U. Pittsburgh

Diane Maresco, Ph.D. OSU in MolGen; student 1991-1997. Scientist Queensland U., Brisbane, AU

Kathleen Miller, Ph.D. OSU in MolGen; student 1991-1997. Staff Scientist, DNAX, Palo Alto, CA

Malcolm Lowry, Ph.D. OSU in MolGen; student 1992-1998. Asst Prof, Oregon State University.

Chaity Chaudury, Ph.D. OSU in Biochem; student 2000-2005. Fellow UCSF. Douglas Hanahan lab.

Jonghan Kim, Ph.D. OSU in Pharmacokinetics 2002-2004. Fellow Harvard. Dr. Wessling-Resnick lab.

Other Students:

James H. O’Grady, M.S.; Rochester student for MS degree in lab; 1983-1985. Kodak, Inc.

Scott Aberegg, M.D.; OSU med student in lab; 1994-1996. Asst Prof. OSU Dept of Med.

James Leach, M.S.; OSU biochemistry student for MS degree in lab; 1995-1997. Ross Labs., Inc.

Patents: Medarex, Inc. 1985. In the early 1980s I along with Michael Fanger and Paul Guyre of Dartmouth collaborated to start a biotech company to develop two monoclonal antibodies that I had made with their help, mabs 32 and IV.3, directed toward human Fc receptors, antibodies on which I and U of Rochester colleagues held the patents. Wanting to avoid commercial distractions I dropped out of the collaboration, but Mike and Paul went on to establish and develop Medarex, Inc, which became a huge success, being traded on Nasdaq and eventually being sold to Bristol-Meyers in 2009 for $2.4 billion. The company makes therapeutic human antibodies to microbes and cancers. I consider myself the foster father of this biotech company.

Publications: (in parentheses, citations as of August 30, 2005)

Anderson, C.L., and H.M. Grey. 1974. Receptors for aggregated IgG on mouse lymphocytes: Their presence on thymocytes, thymus derived and bone marrow derived lymphocytes. J. Exp. Med. 139:1175-1188. (245)

Anderson, C.L., R.T. Kubo, and H.M. Grey. 1975. Cytophilic properties of β2-microglobulin. J. Immunol. 114:997-1000. (33)

Grey, H.M., C.L. Anderson, C.H. Heusser, and J.T. Kurnick. 1975. Fc receptors on lymphocytes other than B cells in mouse and man. In Membrane Receptors of Lymphocytes. M. Seligmann, J.L. Preud'homme and F.M. Kourilski, editors. North Holland Publishing Co., The Netherlands, published by Elsevier Exerpta Medica in the INSERUM Symposia Series, 1:185-192.

Grey, H.M., C.L. Anderson, K. Von Eschen, C. Heusser, and J. Chiller. 1977. Structural and functional heterogeneity of Fc receptors. Cold Spring Harbor Symposia on Quantitative Biology, Vol. XLI, p. 315-321.

Anderson, C.L., and H.M. Grey. 1977. Solubilization and partial characterization of cell membrane Fc receptors. J. Immunol. 118:819-825. (50)

Heusser, C.H., C.L. Anderson, and H.M. Grey. 1977. Receptors for IgG: Subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J. Exp. Med. 145:1316-1327. (195)

Anderson, C.L., and H.M. Grey. 1978. Physicochemical separation of two distinct Fc receptors on mouse macrophage-like cell lines. J. Immunol. 121:648-652. (48)

Grey, H.M., and C.L. Anderson. 1980. Structural characteristics of Fc receptors on macrophages. In Mononuclear Phagocytes: Functional Aspects. R. Van Furth, editor. Martinus Nijhoff Publishing Co., The Hague, pp. 757-776.

Anderson, C.L. 1980. The murine macrophage Fc receptor for IgG2b is lipid dependent. J. Immunol. 125:538-540. (7)

Anderson, C.L., and W.S. Stillman. 1980. The Raji cell assay for immune complexes. Evidence for detection of Raji-directed immunoglobulin G antibody in sera from patients with systemic lupus erythematosus. J. Clin. Invest. 66:353-360. (69)

Anderson, C.L., and G.N. Abraham. 1980. Characterization of the Fc receptor for IgG on a human macrophage cell line, U937. J. Immunol. 125:2735-2741. (148)

Anderson, C.L., and H.L. Spiegelberg. 1981. Macrophage receptors for IgE: Binding of IgE to specific IgE Fc receptors on a human macrophage cell line, U937. J. Immunol. 126:2470-2473. (89)

Goldberg, M.J., M.M. Kaplan, C.L. Anderson, T. Mitamura, D.S. Matloff, V.W. Pinn, and V. Agnello. 1982. Evidence against an immune complex pathogenesis of primary biliary cirrhosis. Gastroenterology 83:677-683. (25)

Anderson, C.L. 1982. Isolation of the receptor for IgG from a human monocyte cell line (U937) and from human peripheral blood monocytes. J. Exp. Med. 156:1794-1806. (120)

Anderson, C.L. 1983. Characterization of human macrophage Fc receptors: Binding of IgG and IgE to the macrophage line, U937. In The Structure and Function of Fc Receptors. F. Paraskevas and A. Froese, editors. Marcel Dekker, Inc., pp. 33-52.

Livingston, J.N., B.R. Saran, C.D. Rose, and C.L. Anderson. 1985. Rapid effect of insulin on the cycling of the insulin receptor in a human monocyte cell line (U937). Diabetes 34:403-408. (9)

Anderson, C.L., J.M. Spence, T.S. Edwards, and J. Nusbacher. 1985. Characterization of a polyvalent antibody directed against the IgG Fc receptor of human mononuclear phagocytes. J. Immunol. 134:465-470. (23)

Jones, D.H., J. Nusbacher, and C.L. Anderson. 1985. Fc receptor-mediated binding and endocytosis by human mononuclear phagocytes: Monomeric IgG is not endocytosed by U937 cells and monocytes. J. Cell Biol. 100:558-564. (29)

Jones, D.H., R.J. Looney, and C.L. Anderson. 1985. Two distinct classes of IgG Fc receptors on a human monocyte line (U937) defined by differences in binding of murine IgG subclasses at low ionic strength. J. Immunol. 135:3348-3353. (112)

Rosenfeld, S.I., R.J. Looney, J.P. Leddy, D.C. Phipps, G.N. Abraham, and C.L. Anderson. 1985. Human platelet Fc receptor for IgG: Identification as a 40 kD membrane protein shared by monocytes. J. Clin. Invest. 76:2317-2322. (200)

Looney, R.J., G.N. Abraham, and C.L. Anderson. 1986. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J. Immunol. 136:1641-1647. (372)

Looney, R.J., D.H. Ryan, K. Takahashi, H.B. Fleit, H.J. Cohen, G.N. Abraham, and C.L. Anderson. 1986. Identification of a second class of IgG Fc receptors on human neutrophils: A 40 kD molecule found also on eosinophils. J. Exp. Med. 163:826-836. (183)

Anderson, C.L., P.M. Guyre, J.C. Whitin, D.H. Ryan, R.J. Looney, and M.W. Fanger. 1986. Monoclonal antibodies to Fc receptors for IgG on human mononuclear phagocytes: Antibody characterization and induction of superoxide production in a monocyte cell line. J. Biol. Chem. 261:12856-12864. (277)

O'Grady, J.H., R.J. Looney, and C.L. Anderson. 1986. The valence for ligand of the human mononuclear phagocyte high affinity IgG Fc receptor is one. J. Immunol. 137:2307-2310. (17)

Anderson, C.L., and R.J. Looney. 1986. Review: Human Leukocyte IgG Fc Receptors. Immunology Today 7:264-266. (450)

Shen, L., P.M. Guyre, C.L. Anderson, and M.W. Fanger. 1986. Heteroantibody mediated cytotoxicity: Antibody to the high affinity Fc receptor for IgG mediates cytotoxicity by human monocytes which is enhanced by gamma interferon and is not blocked by human IgG. J. Immunol. 137:3378-3383. (92)

Anderson, C.L., and R.J. Looney. 1987. IgG Fc receptors of human leukocytes. In Meth. Enz. Vol. 150:524-536, 1987. (20)

Anderson, C.L., D.H. Ryan, R.J. Looney, and P.C. Leary. 1987. Polymorphism of the human monocyte 40 kD receptor for IgG. J. Immunol. 138:2254-2256. (105)

Rosenfeld, S.I., D.H. Ryan, R.J. Looney, C.L. Anderson, G.N. Abraham, and J.P. Leddy. 1987. Human platelet Fc receptors: Quantitative expression correlates with functional responses. J. Immunol. 138:2869-2873. (54)

Looney, R.J., C.L. Anderson, D.H. Ryan and S.I. Rosenfeld. 1987. Structural polymorphism of the human platelet Fc receptor does not correlate with variations in quantitative expression. J. Immunol. 141:2680-2683. (29)

Ceuppens, J.L., M.L. Baroja, F.V. Vaeck and C.L. Anderson. 1988. A defect in the membrane expression of high affinity 72 kD Fc receptors on phagocytic cells in four healthy subjects. J. Clin. Invest. 82:571-578. (53)

Rosenfeld, S.I. and C.L. Anderson. 1989. Fc receptors of human platelets. In Platelet Immunology. Editors T.J. Kunicki and J.N. George. J.B. Lippincott, Philadelphia. pp 337-353.

Peltz, G., K. Frederick, C.L.Anderson and B.M. Peterlin. 1988. Characterization of the human monocyte high affinity Fc receptor. Mol. Immunol. 25:243-250. (25)

Anderson, C.L. 1989. Human leukocyte Fc receptors for IgG: Three distinct classes. In Clinical Uses of Monoclonal Antibodies, Editors R.A.P. Koene and W.J.M. Tax. Sandoz b.v. Uden. Pages 23-29.

Anderson, C.L. 1989. Structural and functional polymorphism of human Fc receptors for IgG. In Chemical Immunology 47:1-20. (26)

Anderson, C.L. 1989. Human IgG Fc receptors. Clin. Immunol. and Immunopath. 53:S63-S71. (47)

Petty, H.R., J.W. Francis and C.L. Anderson. 1989. Cell surface distribution of Fc receptors II and III on living human neutrophils before and during antibody dependent cellular cytotoxicity. J. Cell. Physiol. 141:598-605. (29)

Anderson, G.P. and C.L. Anderson. 1990. Signal transduction by the platelet Fc receptor. Blood. 76:1165-1172. (75)

Ravetch, J.V. and C.L. Anderson. 1990. The FcγR family: Proteins, transcripts and genes. In Fc Receptors and the Action of Antibodies. Ed. H. Metzger, American Society of Microbiology. pp 211-238.

van de Winkel, J.G.J. and C.L. Anderson. 1990. Biological Functioning of Human IgG Fc Receptors. Ann. Inst. Pasteur, Forum d'Immunologie. 141:64-67.

Gosselin, E.J., M.F. Brown, C.L. Anderson, T.F. Zipf, and P.M. Guyre. 1990. The Monoclonal Antibody 41H16 Detects the Leu-4 Responder Form of Human FcγRII. J. Immuno. 144:1817-1822. (88)

Anderson, C.L., L. Shen, D.M. Eicher, M.D. Wewers, and J.K. Gill. 1990. Phagocytosis mediated by three distinct Fcγ receptor classes on human leukocytes. J. Exp. Med. 171:1333-1346. (168)

Anderson, C.L., R.J. Looney, D.J. Culp, D.H. Ryan, H.B. Fleit, M.J. Utell, M.W. Frampton, P.D. Manganiello, and P.M. Guyre. 1990. Alveolar and peritoneal macrophages bear three distinct classes of Fc receptors for IgG. J. Immunol. 145:196-201. (47)

Sedmak, D.D., D.H. Davis, U. Singh, and C.L. Anderson. 1991. Distribution of IgG Fc Receptors in the Human Placenta and on Endothelial Cells: An Immunohistochemical Study. Am. J. Path. 138:175-181 (80)

Kindt, G.C., J.G.J. van de Winkel, S.A. Moore, and C.L. Anderson. 1991. Identification and structural characterization of Fc receptors on pulmonary alveolar macrophages. Am. J. Physiol. 260: L403-L411. (13)

Anderson, G.P., J.G.J. van de Winkel, and C.L. Anderson. 1991. Anti-CD41 monoclonal antibody-induced platelet activation requires Fc receptor-dependent cell-cell interaction. Br. J. Hematology. 79: 75-83. (47)

Van de Winkel, J.G.J. and C.L. Anderson. 1991. Biology of human IgG Fc receptors. J. Leuko. Biol. 49:511-524. (Outstanding Review Award, 1996) (333)

Van de Winkel, J.G.J., L.K. Ernst, C.L. Anderson, and I.-M. Chiu. 1991. Gene organization of the human high-affinity receptor for IgG, FcγRI (CD64). Characterization and evidence for a second gene. J. Biol. Chem. 266: 13449-13455. (53)

L.K. Ernst, J.G.J. Van de Winkel, I.-M. Chiu, and C.L. Anderson. 1992. Three genes for the human high-affinity receptor for IgG (FcγRI) encode four distinct transcripts. J. Biol. Chem. 267:15692-15700. (61)

CITATION INDEX: April 14, 1993. Computer-assisted citation index performed on this date yielded 51 citations per publication (range 0-333).

Lairmore, M.D., Cuthbert, P.S., Utley, L.L., Morgan, C.J., Dezzutti, C.S., Anderson, C.L., and D.D. Sedmak. 1993. Cellular Localization of CD4 in the Human Placenta: Implications for Maternal-to-Fetal Transmission of Human Immunodeficiency Virus. J. Immunol. 151:1673-1681. (35)

L.K. Ernst, A.-M. Duchemin, and C.L. Anderson. 1993. Association of the high affinity receptor for IgG (FcγRI) with the gamma subunit of the IgE receptor. Proc. Nat. Acad. Sci. USA 90:6023-6027. (140)

Anderson, C.L. and D.H. Conrad. 1993. Human IgG and IgE Fc receptor structure and function. In Clinical Aspects of Immunology. Editors F.S. Rosen et al. Fifth Edition. Blackwell, Oxford. 1:221-239.

Anderson, C.L., D.C. Sedmak, and M.D. Lairmore. 1994. The Vertical Transmission of HIV: The Placenta as Barrier. In Pediatric Aids: The Challenge of HIV Infection in Infants, Children, and Adolescents. Editors P. Pizzo and C. Wilfert. Second Edition. 159-168.

Osborne, J.M., G.W. Chacko, J.T. Brandt, and C.L. Anderson. 1994. Ethnic variation in frequency of FcγRIIa high responder/low responder alleles as determined with allele specific oligonucleotide probes. J. Immunol. Methods. 173:207-217. (84)

Duchemin, A.-M., L.K.Ernst, and C.L.Anderson. 1994. Clustering of the high affinity Fc receptor for IgG (FcγRI) results in phosphorylation of its associated FcRγ-chain. J. Biol. Chem. 269:12111-12117. (50)

Chacko, G.C., A.-M. Duchemin, K.M.Coggeshall, J.M.Osborne, J.T.Brandt, and C.L.Anderson. 1994. Clustering of the platelet FcγRII induces noncovalent association with the tyrosine kinase p72syk. J. Biol. Chem. 269:32435-23440. (72)

Van de Winkel, J.G.J. and Anderson, C.L. 1995. CD32 cluster workshop report. in Leukocyte Typing V, V.1 Editors S.F. Schlossman et al. Oxford University Press, Oxford, United Kingdom. 823-826.

Osborne, J.M., Brandt, J.T., Chacko, G.W., Anderson, C.L. 1995. CD32 dependence of antibody-mediated platelet aggregation. in Leukocyte Typing V, V.2 Editors S.F. Schlossman et al. Oxford University Press, Oxford, United Kingdom. 1251-1255.

Anderson, C.L., G.W. Chacko, J.M. Osborne, and J.T. Brandt. 1995. The Fc receptor for IgG (FcγRII) on human platelets. Seminars in Thrombosis and Hemostasis. 21:1-9. (47)

Brandt, J.T., C.E. Isenhart, J.M. Osborne, A. Ahmed, and C.L. Anderson. 1995. On the role of platelet FcγRIIA phenotype in heparin-induced thrombocytopenia. Thrombosis and Haemostasis. 74:1564-1572. (71)

Marsh, C.B., C.L. Anderson, M.P. Lowe, and M.D. Wewers. 1996. Monocyte IL-8 release is induced by two independent Fc(R-mediated pathways. J. Immunol. 157:2632-2637. (23)

Chacko, G.W., J.M. Osborne, J.T. Brandt, and C.L. Anderson. 1996. FcγR on Platelets. In Human IgG Fc Receptors. Ed. J.G.J. van de Winkel and P.J.A. Capel. Publisher R.B. Landes Co., Molecular Biology Intelligence Unit. pp107-122. (13)

Maresco, D.L., E. Chang, K.S. Theil, U. Franke, and C.L. Anderson. 1996. The three genes of the human FcγRI gene family flank the centromere of chromosome 1 at 1p12 and 1q21. Cell Genetics and Cytogenetics. 73:157-163. (5)

Leach, J.L., D.D. Sedmak, J.M. Osborne, B. Rahill, M.D. Lairmore, and C.L. Anderson. 1996. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: Implications for maternal-fetal antibody transport. J. Immunol. 157:3317-3322. (98)

Miller, K.L., A.-M. Duchemin, and C.L. Anderson. 1996. A novel role for the Fc receptor γ subunit: Enhancement of FcγR ligand affinity. J. Exp. Medicine. 183:2227-2234. (44)

Chacko, G.W., J.T.Brandt, K.M. Coggeshall, and C.L. Anderson. 1996. Phosphatidylinositol 3-kinase and p72syk noncovalently associate with the low affinity Fcγ on human platelets through an ITAM: Reconstitution with synthetic phosphopeptides. J. Biol. Chem. 271:10775-10781. (72)

Duchemin, A.-M. and C.L. Anderson. 1997. Association of non-receptor protein tyrosine kinases with the FcγRI γ-chain complex in monocytic cells. J. Immunol. 158:865-871 (29)

Junghans, R.P. and C.L. Anderson. 1996. The protection receptor for IgG catabolism is the b2-microglobulin-containing neonatal intestinal transport receptor. Proc. Natl. Acad. Sci. 93:5512-5516. (164)

Brandt, J.T., C.J. Julius, J.M. Osborne, and C.L. Anderson. 1996. The mechanism of platelet aggregation induced by HLA-related antibodies. Thrombosis and Haemostasis. 76:774-779. (10)

Liu, Z., D.C. Roopenian, X. Zhou, G.J. Christianson, L.A. Diaz, D.D. Sedmak, and C.L. Anderson. 1997. (2-microglobulin-deficient mice are resistant to bullous pemphigoid. J. Exp. Med. 186:777-784. (15)

Sedmak, D.D., B.M. Rahill, J.M. Osborne, J.L. Leach, M.D. Lairmore, R.P. Junghans, and C.L. Anderson. 1996. Human endothelial cells express FcRp, the IgG protection receptor. Unpublished.

Lowry, M.B., A.-M. Duchemin, J.M. Robinson, and C.L. Anderson. 1998. Functional separation of pseudopod extension and particle internalization during Fc( receptor-mediated phagocytosis. J. Exp. Med. 187:161-176. (40)

Ernst, L.K., A.-M. Duchemin, K.L. Miller, and C.L. Anderson. 1998. Molecular Characterization of Six Variant Fc( Receptor Class I (CD64) Transcripts. Mol. Immunol. 35:943-954. (8)

Maresco, D.L., J.M. Osborne, D. Cooney, F.M. Coggeshall, and C.L. Anderson. 1999.

The SH2-containing 5’-inositol phosphatase (SHIP) is tyrosine phosphorylated after Fc( receptor clustering in monocytes. J. Immunol. 162:6458-6465 (17)

Maresco, D.L., L.E. Blue, L.L. Culley, R.P.Kimberly, C.L. Anderson, and K.S. Theil. 1998. Localization of FCGR1 encoding Fc(RI in primates: Molecular evidence for 2 pericentric inversions during the evolution of human chromosome 1. Cell Genetics and Cytogenetics. 82:71-74 (13)

Tridandapani, S., M. Pra, J.R. LaDine, S. Garber, C.L. Anderson, and K.M. Coggeshall, 1999. Protein interactions of src homology 2 (SH2) domain-containing inositol phosphatase (SHIP): Association with Shc displaces SHIP from Fc(RIIb in B cells. J. Immunol. 162:1408-1414 (30)

Lowry, M.B, A.-M. Duchemin, K.M. Coggeshall, J.M. Robinson, and C.L. Anderson. 1998. Chimeric receptors composed of PI3-kinase domains and Fcγ receptor ligand-binding domains mediate phagocytosis in COS fibroblasts. J. Biol. Chem. 273:24513-24520. (23)

Miller, K.L., A.-M. Duchemin, L.K. Ernst, and C.L. Anderson. 2000. Characterization of the two-extracellular domain form of Fc( receptor class I: A product of the B gene. Unpublished.

Miller, K.L., S.A. Garber, A.-M. Duchemin, and C.L. Anderson. 2000. Homodimerization of the ligand-binding ( chains of the high affinity Fc receptor for IgG (Fc(RI). Unpublished.

Tridandapani,S, T.W. Lyden, J.L. Smith, K.M. Coggeshall, and C.L. Anderson. 2000. The adapter protein LAT enhances Fc(R-mediated signal transduction in myeloid cells. J. Biol. Chem. 275:20480-20487. (19)

Lyden, T.W., J.M. Robinson, S. Tridandapani, J.-P.Teillaud, S.A.Garber, J.M. Osborne, J. Frey, P. Budde, C.L. Anderson. 2001. The Fc receptor for IgG expressed in the villus endothelium of human placenta is Fc(RIIb2. J. Immunol. 166:3882-3889. (14)

Tridandapani,S., K. Siefker, J.-L. Teillaud, J.E. Carter, M.D. Wewers, and C.L. Anderson. 2002. Regulated expression and inhibitory function of Fc(RIIb in human monocytic cells. J. Biol. Chem. 277: 5082-5089. (27)

Lyden, T.W., C.L. Anderson, and J.M. Robinson. 2002. The endothelium but not the syncytiotrophoblast of human placenta expresses caveolae. Placenta. 23:640-652. (8)

Tridandapani, S., Y. Wang, C.B. Marsh, and C.L. Anderson. 2002. SH2 domain-containing inositol phosphatase (SHIP) regulates NFκB-dependent gene transcription by phagocytic Fc(R. J. Immunol. 169:4370-4378. (16)

Takizawa,T., C.L. Anderson, and J.M. Robinson. 2003. A new method to enhance contrast of ultrathin cryosections for immunoelectron microscopy. J. Histochem. Cytochem. 51:31-39. (2)

Roopenian, D.C., G.J. Christianson, T.J. Sproule, A.C. Brown, S. Akilesh, N. Jung, S. Petkova, E.Y. Choi, L. Avanessyan, D.J. Shaffer, and C.L. Anderson. 2003. The MHC Class I-like IgG receptor (FcRn) controls perinatal IgG transport, IgG homeostasis, and the fate of IgG-Fc-coupled drugs. J. Immunol. 170: 3528-3533. (10)

Chaudhury, C., S. Mehnaz, J.M. Robinson, W.L. Hayton, D.K. Pearl, D.C. Roopenian, and C.L. Anderson. 2003. The MHC-related Fc receptor for IgG binds albumin and prolongs its lifespan. J. Exp. Med. 197:315-322 (9)

Pengal, R.A., L. P. Ganesan, H. Fang, C.B. Marsh, C.L. Anderson, and S. Tridandapani. 2003. SHIP-2 inositol phosphatase is inducibly expressed in human monocytes and serves to regulate Fc( receptor-mediated signaling. J. Biol. Chem. 278:22657-22663.

Tridandapani, S. and C.L. Anderson. 2004. Review: Regulation of Phagocytosis by Fc(RIIb and Phosphatases. In Molecular Mechanisms of Phagocytosis. Ed C. Rosales. Landes Biosciences Publisher.

Takizawa, T, Anderson, C.L., and J.M. Robinson. 2005. A novel Fc(R-defined, IgG-containing organelle in placental endothelium. J. Immunol. 175: 2331-2339.

Citation Indices: August 31, 2005. Citation index on this date is 78. h-index is 40, cf Nature 436:900-901, 2005. CitationsCLA05.xls

Kim, J, CL Bronson, WL Hayton, MD Radmacher, DC Roopenian, JM Robinson, and CL Anderson, 2006. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as is produced by the liver. Am.J.Physiol. 290:G352-G360.

Chaudhury, C, CL Brooks, DC Carter, and CL Anderson. 2006. FcRn binds albumin and IgG differently but salvages both similarly. Biochemistry. 45:4983-4990

Wani,MA, Haynes,LD, Kim,J, Bronson,CL, Chaudhury,C, Mohanty,S, Waldmann,TA, Robinson,JM, CL Anderson. 2006. Familial hypercatabolic hypoproteinemia caused by FcRn deficiency due to mutant (2-microglobulin gene. Proc. Natl. Acad. Sci. 103:5084-5089.

Bronson, CL, J Kim, C Chaudhury, WL Hayton, TM Oberyszyn, DC Roopenian, JM Robinson, and CL Anderson. 2006. The MHC-related receptor for IgG, FcRn, is a mediator of the transendothelial flux of albumin and IgG. Submitted.

Kim, J, CL Bronson, WL Hayton, MD Radmacher, DC Roopenian, JM Robinson, and CL Anderson, 2006. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces. Am.J.Physiol. 290:G352-G360.

Kim,J, WL Hayton, JM Robinson, CL Anderson. 2007. Kinetics of FcRn-mediated recycling of IgG and albumin in human: Pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin. Immunol. 122:146-155.

Anderson CL, C Chaudhury, J Kim, CL Bronson, MA Wani, S Mohanty. 2006. A perspective: FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 27:343-8.

Chaudhury C, Kim J. Mehnaz S, Wani MA, Oberyszyn TM, Hayton WL, Robinson JM, Anderson CL. 2007. Accelerated transferrin degradation in HFE-deficient mice is associated with increased transferrin saturation. J.Nutr. 136:2993-2998.

Kim J, Bronson CL, Wani WA, Oberyszyn TM, Mohanty S, Chaudhury C, Hayton WL, Robinson JM, and CL Anderson. 2008. β2-Microglobulin deficient mice catabolize IgG more rapidly than FcRn-α-chain deficient mice. Exp Biol Med. 233:603-609.

Kim J, Mohanty S, Ganesan LP, Hua K, Jarjoura D, Hayton WL, Robinson JM and CL Anderson. 2009. FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus. J. Immunol. 182:2583-2589. PMC2676880

Mohanty S, Kim J, Ganesan LP, Phillips GS, Hua K, Jarjoura D, Hayton WL, Robinson JM, and CL Anderson. 2010. IgG is transported across the mouse yolk sac independently of FcγRIIb. J. Reprod. Immunol. 84:133-144.

Ganesan LP, Mohanty S, Kim J, Clark KR, Robinson JM, and CL Anderson. 2011. Rapid and efficient clearance of blood-borne virus by liver endothelium. PLoS Pathogens. 7(9): e1002281. doi:10.1371/journal.ppat.1002281. PMID 21980295

Ganesan LP, Kim J, Wu Y, Mohanty S, Phillips GS, Birmingham DJ, Robinson JM, and CL Anderson. 2012. FcγRIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol. 189(10):4981-8. doi: 10.4049/jimmunol.1202017. Epub 2012 Oct 10. PMID: 23053513

Mohanty S, Kim J, Ganesan LP, Phillips GS, Robinson JM, and CL Anderson, 2013. Abundant intracellular IgG in enterocytes and endoderm lacking FcRn. PLoS One. 2013 Jul 29;8(7):e70863. doi: 10.1371/journal.pone.0070863. Print 2013. PMID: 23923029

Anderson, CL. 2013. Alternative Explanation, eLetter-to-Editor about Zhi et al paper, Cooperative integrin/ITAM signaling in platelets enhances thrombus formation in vitro and in vivo. Blood. 121:1858-1867. PMID 23264598

Anderson CL & J Kim. 2013. Preview: Surmounting an Impasse of FcRn Structure. Structure. 2013 Nov 5;21(11):1907-8.doi: 10.1016/j.str.2013.10.009. PMID 24210225

Anderson CL. 2014. Opinion: There’s been a flaw in our thinking. Frontiers in Immunology, Immunotherapies and Vaccines. 31 October 2014 | doi: 10.3389/fimmu.2014.00540

Ganesan LP, Mates JM, Cheplowitz AM, Avila CL, Zimmerer JM, Maiseyeu A, Robinson JM, and CL

Anderson. 2016. Scavenger receptor B1, the HDL receptor, is expressed abundantly in liver sinusoidal endothelial cells. Scientific Reports.

Anderson CL. 2015. The Liver Sinusoidal Endothelium Reappears after Eclipse by the Kupffer Cell: A 20th Century Biological Delusion Corrected. J. Leuko. Biol. 98:875-876. PM:26628636.

Anderson CL, LP Ganesan, and JM Robinson. 2015. The biology of the classical Fcγ receptors in non-hematopoietic cells. Imm. Reviews. 268:236-240. PM:26497524

Mates JM, Yao Z, Cheplowitz AM, Suer O, Phillips GS, Kweik JJ, Murugesan VSR, Kim J, Robinson JM, Ganesan LP, and CL Anderson. 2017. Mouse liver sinusoidal endothelium eliminates HIV-like particles from blood at a rate of 100 million per minute by a second-order kinetic process. Front. Immunol. 8:35. doi: 10.3389/fimmu.2017.00035

Yao Z, JM Mates, AM Cheplowitz, LP Hammer, A Maiseyeu, GS Phillips, MD Wewers, MVS Rajaram, JM Robinson, CL Anderson, and LP Ganesan. 2016. Blood-borne LPS is rapidly eliminated by liver sinusoidal endothelial cells via HDL. J Immunol. 197(6):2390-2399. doi: 10.4049/jimmunol.1600702.

Current Grants:

R01 AR066330 (PIs Anderson, Ganesan, Robinson); new

NIH/NIARD; Immune Complex Elimination by Sinusoid Endothelial FcγRIIb: Mechanism and Disease

4/16/2014- 3/31/2019

30%; $344,791

An hypothesis describing how sinusoidal endothelium destroys small immune complexes.

Prior Grants Funded and Accepted: (Excluding start-up, small grants, and un-accepted grants)

R01 HD059912-01 (Anderson, PI); new

NIH/NICHD; FcγRIIb protects fetus from allograft rejection

4/1/09 – 03/31/14

30%; $300,000

An hypothesis explaining function of FcγRIIb in human placental villus endothelium

R01 AI057530 (Anderson, PI)

NIH/NIAID; FcRn binds and transports albumin

4/1/05-12/31/09

15%; $250,000

Chemical and biological details of albumin binding to FcRn.

RO1 CA/AI88054 (Anderson, PI)

NIH/NCI/NIAID; How FcRn prolongs IgG lifespan

4/1/01 – 3/31/06 (J.M.Robinson, co-PI);

20%; $166,000.

Study of mechanism by which FcRn protects IgG from usual catabolic degradation.

P01 CA95426 (Caligiuri, program PI; Anderson, PI project1; Tridandapani, co-PI project1)

Homeostatic control of Fc(R-mediated macrophage function.

10/30/02 – 10/29/07. $208,000 (15% effort).

Regulation of Fc(R-mediated functions. No overlap.

R21 AI50074-01A1 (Anderson, PI; Tridandapani, Co-PI)

Homeostatic Control of Fc(R-triggered macrophage function

6/6/02 - 6/5/03. $200,000 (35% effort for Anderson).

Overlaps first year of following two projects.

NIH R01 AI50074 (Anderson, PI; Tridandapani, Co-PI)

Homeostatic control of Fc(R-mediated macrophage function.

12/01/02 – 11/30/07. $225,000 (40% effort)

Continuation of CA44983.

R01 awarded 12/1/02 but withdrawn 11/15/02 superceded by identical P01

P01 AI40150-01 ZAI1 (Anderson, co-I)

NIH/NIAID; Basic Mechanisms of Chronic Allograft Rejection

4/1/96 - 3/31/05 (M.D. Wewers, PI)

5%; ~$150,000

A vascular remodeling paradigm that may account for chronic graft rejection after organ transplantation.

RO1 HL62054 (Anderson, co-I)

NIH/NIHLB HIV Surveillance Affects Macrophage Function

9/30/98 – 8/32/03 (M.D. Wewers, PI)

5%; $200,000

A hypothesis to explain the high incidence of pulmonary infection in AIDS

RO1 CA44983-15; formerly CA24067-07. (Anderson, PI)

NIH/NCI; Biology of human high affinity Fc receptor for IgG

4/1/87-12/31/01, extended to 12/31/02

20-100%; $192,000.

Structure and function of human Fc( receptors. This grant was funded continuously for 25 years by NIH; It was continued for another 5 years, a total of 30, as the P01 CA95426 above.

RO1 HD35121 (Anderson, PI)

NIH/NICHD; IgG transport in human placenta: The function of FcRn

4/1/97-3/31/00 (administratively extended to 3/31/01)

35%; $180,000

This project studies the function of FcRn in IgG syncytiotrophoblast transport.

Pharmacia & Upjohn – OSU Collaboration (Anderson, PI)

The Mechanism of IgG Transport Across Human Placental Endothelium

6/30/98 – 6/30/99

$73,000 / year total

NIIH R01 CA44983-15 (formerly CA24067-10), total 25 years. (Anderson, PI)

Biology of human Fc receptors for IgG

4/1/87-12/31/02 $132,000 (30 - 100% effort)

Dissects the molecular mechanism of human Fc(R function.

No overlap. Not being renewed; continued as AI50074 above

NIH, K04 AI00363 Research Career Development Award

Fc Receptor Structure and Function

3/1/79 - 2/29-84

PI: CL Anderson, 70% effort

~$55,000 / year direct expenses

NIH, P01 AI21288

Vasculopathic mechanisms in immunologic disease

9/1/84 - 8/31/89

Co-I: CL Anderson, 5% effort; PI: JP Leddy.

NIH, R01 AI21093

Immunologically Relevant Receptors of Human Disease

4/1/84 - 9/30/89

Co-I: CL Anderson, 5% effort; PI: SI Rosenfeld

NIH, R01 HL46652

Platelet Fc Receptor in HIV Thrombocytopenia

3/01/91 - 2/29/95

PI: CL Anderson, 25% effort

~$175,000 / year direct

NIH, RO1 AI32744

Syncytiotrophoblast IgG Fc and HIV Infection

11/1/91 - 6/31/95

Co-PI: CL Anderson, 29% effort

~$150,000 / year direct

Pediatric AIDS Foundation, 50618-20-PG

FcR-mediated maternal fetal HIV transmission

3/1/96 - 2/29/97

PI: CL Anderson, 25% effort

~$78,000 / year direct

01cvbig19.l07

-----------------------

5

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download